Paclitaxel delivered to adventitia attenuates neointima formation without compromising re-endothelialization after angioplasty in a porcine restenosis model

Journal of Endovascular Therapy

Volumn 13, Issue 5, 2006, Pages 616-629

  Tian, Wen ^a   Kuhlmann, Michael T ^a   Pelisek, Jaroslav ^a   Scobioala, Sergiu ^a   Quang, Trong Hung ^a   Hasib, Lekbira ^a   Klocke, Rainer ^a   Jahn, Uli Ruediger ^a   Nikol, Sigrid ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Adventitia; Drug eluting stent; Neointima; Paclitaxel; Restenosis

Indexed keywords

EVANS BLUE; PACLITAXEL;

ADVENTITIA; ANGIOGRAPHY; ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG ELUTING STENT; ENDOTHELIUM; FEMALE; FEMORAL ARTERY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTIMA; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STENOSIS; SWINE;

ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; CONNECTIVE TISSUE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRA-ARTERIAL; KI-67 ANTIGEN; MYOCYTES, SMOOTH MUSCLE; PACLITAXEL; RESEARCH DESIGN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWINE; TUNICA INTIMA; TUNICA MEDIA; VON WILLEBRAND FACTOR;

EID: 33751020538     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/05-1802MR.1     Document Type: Article

References (51)

1. Korovesis S, Karvouni E, Giazitzoglou E, et al. Drug-eluting stents: immediate and long-term results. Hellenic J Cardiol. 2005;46:330-335.
2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
3. Moses JW, Mehran R, Nikolsky E, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1165-1171.
4. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
5. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
6. Valgimigli M, van Mieghem CA, Ong AT, et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated at Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation. 2005;111:1383-1389.
7. Huehns TY, Gonschior P, Hofling B. Adventitia as a target for intravascular local drug delivery. Heart. 1996;75:537-538.
8. Scott NA, Cipolla GD, Ross CE, et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon over-stretch injury of porcine coronary arteries. Circulation. 1996;93:2178-2187.
9. Shi Y, O'Brien JE, Fard A, et al. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 1996;94:1655-1664.
10. Nikol S, Huehns TY, Krausz E, et al. Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Ther. 1999;6:737-748.
11. Pelisek J, Kuehnl A, Rolland PH, et al. Functional analysis of genomic DNA, cDNA, and nucleotide sequence of the mature C-type natriuretic peptide gene in vascular cells. Arterioscler Thromb Vase Biol. 2004;24:1646-1651.
12. Nikol S, Engelmann MG, Pelisek J, et al. Local perivascular application of low amounts of a plasmid encoding for vascular endothelial growth factor (VEGF165) is efficient for therapeutic angiogenesis in pigs. Acta Physiol Scand. 2002;176:151-159.
13. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995;95:1869-1876.
14. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96: 636-645.
15. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol. 2000;36:2325-2332.
16. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-2295.
17. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
18. Straubinger RM, Sharma A, Murray M, et al. Novel Taxol formulations: Taxol-containing liposomes. J Natl Cancer Inst Monogr. 1993;(15): 69-78.
19. Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993;90:9552-9556.
20. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559-564.
21. Ikeno F, Lyons J, Kaneda H, et al. Novel percutaneous adventitial drug delivery system for regional vascular treatment. Catheter Cardiovasc Interv. 2004;63:222-230.
22. Celletti FL, Waugh JM, Amabile PG, et al. Inhibition of vascular endothelial growth factor-mediated neointima progression with angiostatin or paclitaxel. J Vasc Interv Radiol. 2002; 13:703-707.
23. Masaki T, Rathi R, Zentner G, et al. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int. 2004;66:2061-2069.
24. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092.
25. Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. 2001;86:262-264.
26. Pelisek J, Armeanu S, Nikol S. Quiescence, cell viability, apoptosis and necrosis of smooth muscle cells using different growth inhibitors. Cell Prolif. 2001;34:305-320.
27. Bauters C, Isner JM. The biology of restenosis. Prog Cardiovasc Dis. 1997;40:107-116.
28. Li G, Chen SJ, Oparil S, et al. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation. 2000;101:1362-1365.
29. Hu Y, Zhang Z, Torsney E, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest. 2004;113:1258-1265.
30. Fukuda D, Shimada K, Tanaka A, et al. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol. 2004;43:18-23.
31. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-409.
32. Hou D, Rogers PI, Toleikis PM, et al. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation. 2000;102:1575-1581.
33. Bayes-Genis A, Kantor B, Keelan PC, et al. Restenosis and hyperplasia: animal models. Curr Interv Cardiol Rep. 2000;2:303-308.
34. Hutter R, Sauter BV, Reis ED, et al. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. Circulation. 2003;107:1658-1663.
35. Walter DH, Cejna M, Diaz-Sandoval L, et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stems: an alternative strategy for inhibition of restenosis. Circulation. 2004;110: 36-45.
36. Virmani R, Farb A, Kolodgie FD. Histopathologic alterations after endovascular radiation and antiproliferative stents: similarities and differences. Herz. 2002;27:1-6.
37. Liuzzo JP, Ambrose JA, Coppola JT. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol. 2005;17:497-502.
38. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part II. Circulation. 2003;107:2383-2389.
39. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705.
40. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697.
41. Wood S. Polymer problems or doctor error? Deployment glitches with Taxus stent spur disquiet and reassurances. theheart.org. [HeartWire News]; April 29, 2004. Accessed at http://www.theheart.org/article/134247.do on July 20, 2006.
42. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res. 2000;87:184-188.
43. Bauriedel G, Schluckebier S, Mutter R, et al. Apoptosis in restenosis versus stable-angina atherosclerosis: implications for the pathogenesis of restenosis. Arterioscler Thromb Vasc Biol. 1998;18:1132-1139.
44. Luo Z, Sata M, Nguyen T, et al. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation. 1999;99: 1776-1779.
45. Parry TJ, Brosius R, Thyagarajan R, et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol. 2005;524:19-29.
46. Armeanu S, Pelisek J, Krausz E, et al. Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol Ther. 2000;1:366-375.
47. Huehns TY, Krausz E, Mrochen S, et al. Neointimal growth can be influenced by local adventitial gene manipulation via a needle injection catheter. Atherosclerosis. 1999;144:135-150.
48. Pels K, Deiner C, Coupland SE, et al. Effect of adventitial VEGF(165) gene transfer on vascular thickening after coronary artery balloon injury. Cardiovasc Res. 2003;60:664-672.
49. Mikawa T, Gourdie RG. Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev Biol. 1996;174:221-232.
50. Shimizu M, Pelisek J, Nikol S. Vasculogenesis and angiogenesis depend on the developmental origin in the arterial tree. Curr Med Chem. 2002;9:1619-1630.
51. Patel S, Shi Y, Niculescu R, et al. Characteristics of coronary smooth muscle cells and adventitial fibroblasts. Circulation. 2000;101:524-532.